These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27466718)

  • 21. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients.
    Lee HK; Ryu IH; Seo KY; Hong S; Kim HC; Kim EK
    Ophthalmology; 2006 Feb; 113(2):198-205. PubMed ID: 16360211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis.
    Goldstein MH; Tubridy KL; Agahigian J; Furfine E; Magill M; Kovalchin J; Golden K; Zarbis-Papastoitsis G; Soong F; Salapatek AM; Sternberg G; Celniker A
    Eye Contact Lens; 2015 May; 41(3):145-55. PubMed ID: 25915834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
    Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
    Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome.
    Marsh P; Pflugfelder SC
    Ophthalmology; 1999 Apr; 106(4):811-6. PubMed ID: 10201607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
    Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
    Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
    Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
    Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
    Ozen S; Ozer MA; Akdemir MO
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1173-1177. PubMed ID: 28299439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group.
    Nelson JD; Gordon JF
    Am J Ophthalmol; 1992 Oct; 114(4):441-7. PubMed ID: 1415455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of OTX-101, a Novel Nanomicellar Formulation of Cyclosporine A, on Corneal Staining in Patients With Keratoconjunctivitis Sicca: A Pooled Analysis of Phase 2b/3 and Phase 3 Studies.
    Malhotra R; Devries DK; Luchs J; Kabat A; Schechter BA; Shen Lee B; Shettle L; Smyth-Medina R; Ogundele A; Darby C; Bacharach J; Karpecki P
    Cornea; 2019 Oct; 38(10):1259-1265. PubMed ID: 31306284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Pilot Randomized Trial on Safety and Efficacy of a Novel Topical Combined Inhibitor of Janus Kinase 1/3 and Spleen Tyrosine Kinase for GVHD-Associated Ocular Surface Disease.
    Kheirkhah A; Di Zazzo A; Satitpitakul V; Fernandez M; Magilavy D; Dana R
    Cornea; 2017 Jul; 36(7):799-804. PubMed ID: 28445193
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Development of EBI-005: An IL-1 Receptor-1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases.
    Kovalchin J; King B; Masci A; Hopkins E; Fry J; Hou J; Li C; Tenneson K; Weber S; Wolfe G; Collins K; Furfine ES
    Eye Contact Lens; 2018 May; 44(3):170-181. PubMed ID: 28727604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgery.
    Mencucci R; Boccalini C; Caputo R; Favuzza E
    J Cataract Refract Surg; 2015 Aug; 41(8):1699-704. PubMed ID: 26432128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
    Wu D; Chen WQ; Li R; Wang Y
    Cornea; 2015 Jun; 34(6):644-50. PubMed ID: 25909234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
    Lekhanont K; Park CY; Smith JA; Combs JC; Preechawat P; Suwan-Apichon O; Rangsin R; Chuck RS
    J Ocul Pharmacol Ther; 2007 Feb; 23(1):27-34. PubMed ID: 17341147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.
    Baudouin C; Figueiredo FC; Messmer EM; Ismail D; Amrane M; Garrigue JS; Bonini S; Leonardi A
    Eur J Ophthalmol; 2017 Aug; 27(5):520-530. PubMed ID: 28362054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Clinical Trial Comparing the Safety and Efficacy of Topical Tacrolimus versus Methylprednisolone in Ocular Graft-versus-Host Disease.
    Abud TB; Amparo F; Saboo US; Di Zazzo A; Dohlman TH; Ciolino JB; Hamrah P; Dana R
    Ophthalmology; 2016 Jul; 123(7):1449-57. PubMed ID: 27086024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.